Cite
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
MLA
Kamphuis, Esmé, et al. “Real-World Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-Week Results from the BioDay Registry.” Acta Dermato-Venereologica, vol. 104, Feb. 2024, p. adv19454. EBSCOhost, https://doi.org/10.2340/actadv.v104.19454.
APA
Kamphuis, E., Boesjes, C. M., Loman, L., Kamsteeg, M., Haeck, I., Van Lynden-van Nes, A. M. T., Politiek, K., Van der Gang, L. F., De Graaf, M., De Bruin-Weller, M. S., & Schuttelaar, M. L. A. (2024). Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry. Acta Dermato-Venereologica, 104, adv19454. https://doi.org/10.2340/actadv.v104.19454
Chicago
Kamphuis, Esmé, Celeste M Boesjes, Laura Loman, Marijke Kamsteeg, Inge Haeck, Anneke M T Van Lynden-van Nes, Klaziena Politiek, et al. 2024. “Real-World Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-Week Results from the BioDay Registry.” Acta Dermato-Venereologica 104 (February): adv19454. doi:10.2340/actadv.v104.19454.